Revenue	12 Months Ended
Dec. 31, 2024
Revenue Recognition and Deferred Revenue [Abstract]
Revenue	8. Revenue The Company started to manufacture and deliver VELDONA Pet supplements to on-line and off-line distribution channels beginning the third quarter of 2023. Revenue from sales through on-line platform were recognized after the expiration of right of return which was offered for a limited time. Revenue from sales through off-line distribution channels was recognized only to the extent that the product sold was not expected to be returned. $106,329 and $112,555 of contract liabilities were recorded for the cash received in advance from distribution channels as of December 31, 2024 and 2023, respectively. Revenue recognized during the year ended December 31, 2024 and 2023 that was included in the contract liability balance at the beginning of each year were nil.

The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 430
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/430/tableOfContent

Name:	us-gaap_DeferredRevenueDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration